Multiple sclerosis (relapsing) - teriflunomide: evaluation report

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer Genzyme

03 - Patient Access Scheme submission from the technology manufacturer Genzyme

04 - NICE request to the manufacturer for clarification on their submission

05 - Manufacturer clarification response

06 - Consultee Submission - Multiple Sclerosis Society

07 - Consultee Submission -  Multiple Sclerosis Trust

08 - Consultee Submission - Association of British Nurses

09 - Consultee Submission -  United Kingdom Clinical Pharmacy Association

10 - Clinical expert personal perspective

11 -  Clinical expert personal perspective

12 - Patient expert personal perspective

13 - Patient expert personal perspective

14 -  Evidence Review Group Report prepared by York, Centre for Reviews and Dissemination and Centre for Health Economics

15 -  Evidence Review Group erratum

16 -  Evidence Review Group report - factual accuracy check

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 20 September 2013